Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. May 7, 2026; 32(17): 117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy
Pei-Ming Zheng, Li-Bo Ouyang, Rong Wang, Ke-Ying Jing, Chun-Kai Zhu, Department of Clinical Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China
Hui-Jie Gao, Department of Oncology, The First Affiliated Hospital of Henan University, Kaifeng 475000, Henan Province, China
Co-first authors: Pei-Ming Zheng and Li-Bo Ouyang.
Author contributions: Zheng PM conducted the majority of experiments and wrote the manuscript; Zheng PM, Ouyang LB and Wang R designed the study and served as a scientific advisor and guarantor; Wang R corrected the manuscript; Jing KY was involved in applying the analytical tools; Gao HJ and Zhu CK participated in the collection of human material.
Supported by the Henan Provincial Program for Young and Middle-Aged Innovators in Health Science and Technology, No. LJRC2024002; and the Natural Science Foundation of Henan Province, No. 252300421373.
Institutional review board statement: The study protocol was approved by the Henan Provincial People’s Hospital (approval No. 2023-126).
Informed consent statement: Informed consent was obtained from all study participants.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Corresponding author: Pei-Ming Zheng, PhD, Associate Chief Technician, Department of Clinical Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China.
Received: December 18, 2025
Revised: January 13, 2026
Accepted: February 4, 2026
Published online: May 7, 2026
Processing time: 127 Days and 19.5 Hours
Revised: January 13, 2026
Accepted: February 4, 2026
Published online: May 7, 2026
Processing time: 127 Days and 19.5 Hours
Core Tip
Core Tip: Antinuclear antibody (ANA), extractable nuclear antigen (ENA) and systemic inflammation have been implicated in cancer prognosis, their combined role predicting outcomes of gastric cancer patients undergoing immunotherapy. This study confirmed autoantibody, particularly ANA/ENA, along with other indicators serves as independent factors for prognosis in gastric cancer patients undergoing immunotherapy. The assessment of autoantibody profiles provides a novel perspective for optimizing risk stratification and treatment methods.